Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + Metronomic Chemotherapy Induction in Second-Line Metastatic Colorectal Cancer
NCT05462613Phase 3Active, not recruiting
- Sponsor
- CHU de Besançon
- Start
- May 2023
- Primary completion
- Nov 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of regorafenib in colorectal cancer (CRC) (2 arms), sponsored by CHU de Besançon. Primary endpoints: Objective Response Rate at 14 months and Overall Survival at 64 months. Started May 2023; status: active, not recruiting.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05462613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05462613.